Inhibition of pancretic cancer cell growth

• US 20090012018A1
• Filed: 09/13/2005
• Published: 01/08/2009
• Est. Priority Date: 09/13/2004
• Status: Abandoned Application

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Hebrok, Matthias, Pasca Di Magliano, Marina
• Application Number:
  US11/662,853
• Publication Number:
  US 20090012018A1
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/1808 Epidermal growth factor [EGF] urogastrone
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The present invention relates to compositions and methods for inhibition of signal transduction pathways in cancer cells. In particular, the present invention provides methods and compositions comprising Wnt and Hedgehog pathway inhibitors for reducing proliferation of adenocarcinoma cells.

Claims

1. A method comprising contacting a pancreatic adenocarcinoma cell with both a Hedgehog pathway inhibitor and a Wnt pathway inhibitor, under conditions suitable for retarding growth of said pancreatic adenocarcinoma cell.

2. The method of claim 1, wherein said pancreatic adenocarcinoma cell is a human cell.

3. The method of claim 1, wherein said retarding growth comprises inhibiting proliferation of said pancreatic adenocarcinoma cell.

4. The method of claim 1, wherein said retarding growth comprises inducing death of said pancreatic adenocarcinoma cell.

5. The method of claim 4, wherein said inducing death of said pancreatic adenocarcinoma cell is essentially unaccompanied by death of untransformed pancreatic ductal cells.

6. The method of claim 1, wherein said Hedgehog pathway inhibitor is cyclopamine or Gli siRNA.

7. The method of claim 1, wherein the target of said Hedgehog pathway inhibitor is selected from the group consisting of Smoothened, Sonic Hedgehog, Desert Hedgehog, Indian Hedgehog, Gli1 and Gli2.

8. The method of claim 1, wherein said Wnt pathway inhibitor is selected from the group consisting of sulindac, sulindac sulfide, sulindac sulfone, ICAT, dnLef1, and β

-catenin siRNA.

9. The method of claim 1, wherein the target of said Wnt pathway inhibitor is selected from the group consisting of LRP, Frizzled, Wnt, Dishevelled, β

-catenin, Lef and Tcf.

10. The method of claim 1, further comprising assessing Wnt pathway activity in said adenocarcinoma cell by examining nuclear or cytoplasmic accumulation of β

-catenin, prior to said contacting.

11. A method of treating cancer of the pancreas, comprising:

a) providing a Hedgehog pathway inhibitor and a Wnt pathway inhibitor; and

b) administering said Hedgehog pathway inhibitor and said Wnt pathway inhibitor to a subject diagnosed with cancer of the pancreas, under conditions suitable for retarding growth of said cancer.

12. The method of claim 11, wherein said subject is a human.

13. The method of claim 11, wherein said cancer of the pancreas is pancreatic adenocarcinoma.

14. The method of claim 13, wherein said retarding growth of said cancer comprises inhibiting proliferation of at least one cell of said pancreatic adenocarcinoma.

15. The method of claim 13, wherein said retarding growth of said cancer comprises inducing death of at least one cell of said pancreatic adenocarcinoma.

16. The method of claim 15, wherein said inducing death of at least one cell of said pancreatic adenocarcinoma is essentially unaccompanied by death of untransformed pancreatic ductal cells.

17. The method of claim 13, wherein said retarding growth of said cancer comprises reducing volume of said pancreatic adenocarcinoma.

18. The method of claim 11, wherein said Hedgehog pathway inhibitor and said Wnt pathway inhibitor are each formulated in a pharmaceutically acceptable carrier.

19. The method of claim 11, further comprising administering a standard treatment regimen for cancer of the pancreas, to said subject.

20. The method of claim 19, wherein said standard treatment regimen comprises one or more of resection, radiation and chemotherapy.

21. The method of claim 20, wherein said chemotherapy is selected from the group consisting of 5-fluorouracil, and 2′

,2′

-difluorodeoxycytidine.

22. The method of claim 11, further comprising administering an adjunct treatment regimen for cancer of the pancreas, to said subject.

23. The method of claim 22, wherein said adjunct treatment regimen is selected from the group consisting of a platinum analogue, topoisomerase-inhibitor, antimicrotubule agent, proteosome inhibitor, vitamin D analogue, arachidonic acid pathway inhibitor, histone deacytylator inhibitor, farnesyltransferase inhibitor and epidermal growth factor-based therapy.

24. A kit for treating pancreatic adenocarcinoma in a subject, comprising:

a) a Hedgehog pathway inhibitor;

b) a Wnt pathway inhibitor; and

c) instructions for using said Hedgehog pathway inhibitor and said Wnt pathway inhibitor to treat pancreatic adenocarcinoma in a subject.

25. The kit of claim 24, wherein said Hedgehog pathway inhibitor is cyclopamine or Gli siRNA.

26. The kit of claim 24, wherein said Wnt pathway inhibitor is selected from the group consisting of sulindac, sulindac sulfide, sulindac sulfone, ICAT, dnLef1, and β

-catenin siRNA.